At opening in 2018, our site was the world’s largest dedicated cell and gene therapies (CGT) manufacturing facility.
Our people are dedicated to making more therapies available to patients.
We are approved for commercial manufacture.
Our 300,000 square foot facility is our US center of excellence for process development activities of cell therapies, gene therapies and viral vectors. The site includes large research and development laboratories dedicated to developing future cell and gene therapies innovations and technologies. In 2021, Lonza Houston was officially approved for commercial production of a gene therapy by the FDA.
Many of our customers start process development activities in the process development laboratories, before naturally transitioning to the manufacturing floor into one of our cGMP suites located under the same roof. We purposefully built the facility with future capacity in mind to enable scale-up manufacturing in line with our customer’s needs, so that, together, we can make more therapies available to patients.
Global Head of Process Development
Sustainability